SEARCH
検索詳細
渡邊 雄大 (ワタナベ ユウダイ)
| 北海道大学病院 医療・ヘルスサイエンス研究開発機構 | 特任講師 |
| 総合イノベーション創発機構ワクチン研究開発拠点 | 特任講師 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID
研究活動情報
■ 論文- Hokkaido phase II study of photo-immunotherapy combination with ASP-1929 for recurrent or persistent EGFR-positive vulvar, vaginal, and cervical cancers not amenable to further radiotherapy (HICARi study).
Hiroshi Asano; Hiroyuki Yamazaki; Hiroko Matsumiya; Isao Yokota; Kazufumi Okada; Ryutaro Yamamoto; Kanako C Hatanaka; Yuko Sasajima; Michiko Nagamine; Yutaka Hatanaka; Fumi Kato; Junko Takahama; Takahiro Tsuboyama; Yudai Watanabe; Naoko Okita; Hidemichi Watari
Journal of gynecologic oncology, 2026年05月18日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Photoimmunotherapy using ASP-1929 (ASP1929-PIT) is a novel approach targeting epidermal growth factor receptor (EGFR)-expressing tumors. ASP-1929, an anti-EGFR monoclonal antibody conjugated to IRDye 700DX (IR700), binds to EGFR in tumor cells. Upon exposure to 690-nm red laser light, IR700 is activated, disrupting the cellular membrane. Approved in Japan for head and neck cancer, this therapy is the first of its kind globally. Given its mechanism, ASP-1929 may also treat other EGFR-positive malignancies accessible to red light. Thus, we are conducting a phase II clinical trial of ASP1929-PIT for localized recurrent and persistent vulvar, vaginal, and cervical cancers refractory to radiotherapy (RT). These severely impact quality of life, highlighting an unmet need. METHODS: This single-arm, open-label, phase II investigator-initiated trial evaluated the efficacy and safety of ASP1929-PIT for recurrent or persistent vulvar, vaginal, or cervical cancer post-RT (jRCT2011240034). Participants had EGFR expression confirmed by immunohistochemistry, prior RT (including chemoradiotherapy) for the primary lesion, and at least one measurable vulvar, vaginal, or cervical lesion. Patients with uncontrolled distant disease or suspected mucosal invasion of the rectum or lower urinary tract were excluded. ASP-1929 (640 mg/m²) was administered via a 2-hour intravenous infusion, followed 20-28 hours later by 690-nm laser illumination. Day 1 was designated for ASP-1929 administration, with efficacy assessed between days 29 and 56. Patients could receive up to three additional treatments if a complete response was not achieved. The primary outcome was tumor shrinkage in laser-treated lesions. Sixteen patients were enrolled, with the first 4 forming a safety cohort. TRIAL REGISTRATION: Japan Registry of Clinical Trials Identifier: jRCT2011240034. - Haemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative: an open-label, single-centre phase Ib study protocol in Japan.
Kazuya Sakai; Kiyoshi Asada; Yudai Watanabe; Hiroshi Azuma; Hiromi Sakai; Masato Kasahara; Masanori Matsumoto
BMJ open, 16, 1, e110183, 2026年01月22日, [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: Haemoglobin vesicles (HbVs) (product name, NMU-HbVs [Nara Medical University-Haemoglobin Vesicles]), which contain purified human haemoglobin encapsulated within liposomes, have been developed as a potential alternative to blood transfusions in emergency situations. A previous phase I study examined doses up to 100 mL in 11 healthy volunteers. Here, we describe the protocol for a phase Ib study, wherein we will evaluate the safety and pharmacokinetics of NMU-HbV in healthy Japanese adults. METHODS AND ANALYSIS: This single-centre, open-label, dose-escalation study will enrol 16 healthy volunteers divided into four cohorts. Planned doses are 100 mL for cohorts 1 and 2, 200 mL for cohort 3 and 400 mL for cohort 4, with infusion rates gradually increasing to a maximum of 5.0 mL/min. The primary endpoint will be safety, which will be assessed as the incidence of adverse events within 14 days and significant clinical changes within 72 hours after administration. Safety evaluations will include subjective symptoms, vital signs, electrocardiograms and laboratory test results compared with the baseline. The secondary endpoint will be pharmacokinetics, which will be assessed as changes in NMU-HbV concentration immediately after infusion until day 4 to determine the maximum blood concentration, time to reach the maximum blood concentration, area under the blood concentration-time curve and elimination half-life. This study will provide data on the safety and pharmacokinetic profiles of NMU-HbV at doses up to 400 mL. The findings are expected to support the further development of NMU-HbV as a viable alternative to emergency transfusions. ETHICS AND DISSEMINATION: The study protocol was approved by the Institutional Review Board of Nara Medical University on 10 December 2024. Dissemination plans include publishing in peer-reviewed scientific journals and presentation at international conferences. TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials (jRCT2051240249). Registered on 27 January 2025 (https://jrct.mhlw.go.jp/en-latest-detail/jRCT2051240249). - Protocol for treating lumbar spinal canal stenosis with a combination of ultrapurified, allogenic bone marrow-derived mesenchymal stem cells and in situ-forming gel: a multicentre, prospective, double-blind randomised controlled trial.
Hideki Sudo; Takashi Miyakoshi; Yudai Watanabe; Yoichi M Ito; Kaoru Kahata; Khin Khin Tha; Nozomi Yokota; Hiroe Kato; Tomoko Terada; Norimasa Iwasaki; Teruyo Arato; Norihiro Sato; Toshiyuki Isoe
BMJ open, 13, 2, e065476, 2023年02月02日, [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: In patients with combined lumbar spinal canal stenosis (LSCS), a herniated intervertebral disc (IVD) that compresses the dura mater and nerve roots is surgically treated with discectomy after laminoplasty. However, defects in the IVD after discectomy may lead to inadequate tissue healing and predispose patients to the development of IVD degeneration. Ultrapurified stem cells (rapidly expanding clones (RECs)), combined with an in situ-forming bioresorbable gel (dMD-001), have been developed to fill IVD defects and prevent IVD degeneration after discectomy. We aim to investigate the safety and efficacy of a new treatment method in which a combination of REC and dMD-001 is implanted into the IVD of patients with combined LSCS. METHODS AND ANALYSIS: This is a multicentre, prospective, double-blind randomised controlled trial. Forty-five participants aged 20-75 years diagnosed with combined LSCS will be assessed for eligibility. After performing laminoplasty and discectomy, participants will be randomised 1:1:1 into the combination of REC and dMD-001 (REC-dMD-001) group, the dMD-001 group or the laminoplasty and discectomy alone (control) group. The primary outcomes of the trial will be the safety and effectiveness of the procedure. The effectiveness will be assessed using visual analogue scale scores of back pain and leg pain as well as MRI-based estimations of morphological and compositional quality of the IVD tissue. Secondary outcomes will include self-assessed clinical scores and other MRI-based estimations of compositional quality of the IVD tissue. All evaluations will be performed at baseline and at 1, 4, 12, 24 and 48 weeks after surgery. ETHICS AND DISSEMINATION: This study was approved by the ethics committees of the institutions involved. We plan to conduct dissemination of the outcome data by presenting our data at national and international conferences, as well as through formal publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: jRCT2013210076. - Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review.
Hiroshi Asano; Toshiyuki Isoe; Yoichi M Ito; Naoki Nishimoto; Yudai Watanabe; Saki Yokoshiki; Hidemichi Watari
Cancers, 14, 5, 2022年02月24日, [国際誌]
英語, 研究論文(学術雑誌), Uterine leiomyosarcoma (uLMS) is the most common subtype of mesenchymal tumors in the uterus. This review aims to summarize the current standard therapies and the molecular properties of uLMS for novel molecular-targeted therapies. Although 65% of uLMS cases are diagnosed in stage I, the 5-year overall survival rate is less than 60%. The only effective treatment for uLMS is complete and early resection, and chemotherapy is the main treatment for unresectable advanced or recurrent cases. No chemotherapy regimen has surpassed doxorubicin monotherapy as the first-line chemotherapy for unresectable advanced or recurrent cases in terms of overall survival in phase 3 trials. As a second-line treatment, pazopanib, trabectedin, and eribulin are used, but their therapeutic effects are not sufficient, highlighting the urgent need for development of novel treatments. Recent developments in gene analysis have revealed that homologous recombination deficiency (HRD), including breast cancer susceptibility gene 2 (BRCA2) mutations, are frequently observed in uLMS. In preclinical studies and several case series, poly(adenosine diphosphate-ribose)polymerase inhibitors showed antitumor effects on uLMS cell lines with BRCA2 mutations or HRD and in recurrent or persistent cases of uLMS with BRCA2 mutations. Thus, HRD, including BRCA mutations, may be the most promising therapeutic target for uLMS. - Enantio- and diastereoselective hetero-Diels-Alder reactions between 4-methyl-substituted Rawal's diene and aldehydes catalyzed by chiral dirhodium(II) carboxamidates: catalytic asymmetric synthesis of (-)-cis-aerangis lactone
Yudai Watanabe; Naoyuki Shimada; Masahiro Anada; Shunichi Hashimoto
TETRAHEDRON-ASYMMETRY, 25, 1, 63, 73, 2014年01月
英語, 研究論文(学術雑誌) - P-35 18E-リングビアロシドCの全合成研究(ポスター発表の部)
棚田 文也; 渡邊 雄大; 穴田 仁洋; 橋本 俊一
天然有機化合物討論会講演要旨集, 54, 369, 374, 天然有機化合物討論会, 2012年09月01日
日本語, 18E-Lyngbyaloside C (1), a 14-membered glycosidic macrolide isolated from the marine cyanobacterium Lyngbya bouilloni, has been shown to exhibit cytotoxicity to HeLa cell lines. We previously reported that Rh_2(S-BPTPI)_4 is a highly effective Lewis acid catalyst for endo- and enantioselective hetero-Diels-Alder (HDA) reactions of a diverse range of aldehydes with Danishefsky-type and Rawal's dienes, in which enantioselectivities up to 99% ee have been achieved. In order to demonstrate the utility of this catalytic process, we embarked on the total synthesis of 1. The synthesis of the C1-C8 fragment 9 was initiated with the HDA reaction between Danishefsky-type diene 3a and benzyloxyacetoaldehyde (14) in the presence of 1 mol% of Rh_2(R-BPTPI)_4 to provide dihydropyranone 13 in 83% yield with 91% ee. The Mukaiyama-Michael addition reaction of silyl ketene acetal derived from ethyl acetate to 13 followed by Ito-Saegusa oxidation gave 2,6-disubstituted dihydropyranone 12, which was converted to tetrahydropyran 19. Removal of the benzyl ether followed by incorporation of the thiotetrazole via the Mitsunobu protocol and oxidation of the derived sulfide furnished sulfone 9. The HDA reaction between Rawal's diene (6) and (R)-3-(4-methoxybenzyloxy)-2-methylpropanal (17b) under catalysis by 1 mol% of Rh_2(R-BPTPI)_4 proceeded cleanly and gave, after treatment with acetyl chloride, the desired dihydropyranone 16b in 82% yield with 95:5 diastereoselectivity. Treatment of 16b with MeLi followed by oxidative rearrangement, stereoselective epoxidation and reduction of epoxylactone provided triol 25, which was uneventfully converted to tosylate 26. Cyanide displacement of the O-tosyl group followed by a sequential reduction with DIBAL-H and NaBH_4 furnished alcohol 27. Protection of the C16 hydroxy group as its MEM ether was followed by oxidative removal of the MPM group and Dess-Martin oxidation to produce the C9-C16 fragment 10. A Julia-Kocienski olefination between the C1-C8 fragment 9 and the C9-C16 fragment 10 afforded E-alkene 8. Sequential catalytic hydrogenation of the double bond and cleavage of the benzylidene protecting group furnished diol 28. Further efforts toward the total synthesis of 1 are currently underway. - Enantio- and diastereoselective hetero-Diels-Alder reactions between 2-aza-3-silyloxy-1,3-butadienes and aldehydes catalyzed by chiral dirhodium(II) carboxamidates
Yudai Watanabe; Takuya Washio; Janagiraman Krishnamurthi; Masahiro Anada; Shunichi Hashimoto
CHEMICAL COMMUNICATIONS, 48, 55, 6969, 6971, 2012年
英語, 研究論文(学術雑誌) - A Short, Catalytic, Asymmetric Synthesis of Diospongins A and B by a One-Pot, Sequential Hetero-Diels-Alder/Mukaiyama-Michael Reaction Process
Masahiro Anada; Takuya Washio; Yudai Watanabe; Koji Takeda; Shunichi Hashimoto
European Journal of Organic Chemistry, 2010, 35, 6850, 6854, Wiley, 2010年12月
研究論文(学術雑誌) - THE MUKAIYAMA ALDOL AND MUKAIYAMA-MICHAEL REACTIONS PROMOTED BY COMMERCIALLY AVAILABLE MOLECULAR SIEVES
Masahiro Anada; Takuya Washio; Yudai Watanabe; Shunichi Hashimoto
HETEROCYCLES, 80, 2, 1489, 1503, 2010年03月
英語, 研究論文(学術雑誌) - Highly enantioselective hetero-Diels-Alder reactions between Rawal's diene and aldehydes catalyzed by chiral dirhodium(II) carboxamidates
Yudai Watanabe; Takuya Washio; Naoyuki Shimada; Masahiro Anada; Shunichi Hashimoto
CHEMICAL COMMUNICATIONS, 47, 7294, 7296, 2009年
英語, 研究論文(学術雑誌)
- 18E-リングビアロシドCの合成研究
伊藤元気; 鈴木拓郎; 棚田文也; 渡邊雄大; 竹田幸司; 穴田仁洋; 橋本俊一, 日本薬学会年会要旨集(CD-ROM), 134th, 2014年
- 二核ロジウム錯体の創製を基盤とする不斉ルイス酸触媒反応の開発とその応用
科学研究費助成事業
2010年 - 2012年
渡邊 雄大
これまでLewis酸触媒では報告例がなかったRawalジエンや2-アザ-3-シロキシジエンとアルデヒドとの不斉ヘテロDiels-Alder(HDA)反応において、ロジウム(II)アミダート錯体Rh2(S-BPTPI)4が優れた触媒活性を示すことを見出している。
今年度は、Rh2(S-BPTPI)4存在下、4位にメチル基が置換したRawal型ジエンとアルデヒドとの不斉HDA反応のさらなる基質適用範囲の探索を行った。その結果、本法は芳香族アルデヒドだけではなく脂肪族アルデヒドや共役アルデヒドがジエノフィルとして適用可能で、完璧なエンド選択性かつ最高98%の不斉収率で付加環化生成物が得られることが分かった。また、ヘキサナールとの反応より得られる付加環化生成物をLuche還元してアルコールを単一異性体として得た後、Ferrier型転位反応を行い、生じたアセタールの酸化、オレフィンの還元を行うことでラン科の植物の芳香成分である(+)-cis-エランギスラクトンへ変換することができた。
さらに、Rh(II)錯体存在下でのα位あるいはβ位に不斉中心をもつ光学活性なアルデヒドとRawalジエンとのジアステレオ選択的HDA反応の検討を行った。アキラルな錯体であるRh2(OAc)4やRh2(cap)4を用いた場合、ジアステレオ選択性は劣悪な結果であったが、Rh2(S-BPTPI)4およびRh2(R-BPTPI)4を用いた場合には、反応は低温で円滑に進行し、触媒支配の優先絶対配置をもつ付加環化生成物が高いジアステレオ選択性で得られることが分かった。得られた生成物は、生理活性天然物合成における有用なキラルビルディングブロックになるものと考えられる。
日本学術振興会, 特別研究員奨励費, 北海道大学, 10J02247
